THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC: Form 990, tax year 2019

View the entire original 990 at ProPublica ↗

Organization
THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC (EIN 06-1504413)
Tax period
2019-01-01 to 2019-12-31
Filed
2020-09-30
IRS object ID
202042749349301569
Schema version
2019v5.1
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2020-09-30T16:03:30-05:00ReturnTs
Tax Period End2019-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN271728945PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1PKF O'CONNOR DAVIES LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line13001 SUMMER STREET 5TH FLOOR EASTAddressLine1Txt
CitySTAMFORDCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06905ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2019-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN061504413EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE MULTIPLE MYELOMA RESEARCHBusinessNameLine1Txt
Business Name Line2FOUNDATION INCBusinessNameLine2Txt
FieldValueIRS element (for citing)
Business Name ControlMULTBusinessNameControlTxt
Phone2039721250PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1383 MAIN AVE NO 5TH FLAddressLine1Txt
CityNORWALKCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06851ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonROBERT MIANIPersonNm
Person TitleTREASURER/CFOPersonTitleTxt
Phone2039721250PhoneNum
Signature2020-09-30SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonGARRETT M HIGGINSPreparerPersonNm
PTINP00543209PTIN
Phone2033232400PhoneNum
Preparation2020-09-29PreparationDt

Filing Security Information FilingSecurityInformation

IP Address IPAddress

FieldValueIRS element (for citing)
I Pv4 Address24.190.81.120IPv4AddressTxt
FieldValueIRS element (for citing)
IP2020-09-30IPDt
IP Tm16:03:25IPTm
IP TimezoneEDIPTimezoneCd
Filing License TypePFilingLicenseTypeCd
At Submission Creation Device IdDA39A3EE5E6B4B0D3255BFEF95601890AFD80709AtSubmissionCreationDeviceId
At Submission Filing Device Id9616F4B14A694591D1E716C270910E6FA5556DA3AtSubmissionFilingDeviceId
FieldValueIRS element (for citing)
Tax2019TaxYr
Build TS2021-01-29 14:40:06ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerPAUL GIUSTIPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line1383 MAIN AVE NO 5TH FLAddressLine1Txt
CityNORWALKCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06851ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$47,585,000GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.THEMMRF.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1998FormationYr
Legal Domicile StateCTLegalDomicileStateCd
Activity Or MissionSEE SCHEDULE OActivityOrMissionDesc
Voting Members Governing Body20VotingMembersGoverningBodyCnt
Voting Members Independent18VotingMembersIndependentCnt
Total Employee67TotalEmployeeCnt
Total Volunteers410TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$41,335,585PYContributionsGrantsAmt
CY Contributions Grants$39,651,088CYContributionsGrantsAmt
PY Program Service Revenue$3,610,454PYProgramServiceRevenueAmt
CY Program Service Revenue$2,813,345CYProgramServiceRevenueAmt
PY Investment Income$1,125,389PYInvestmentIncomeAmt
CY Investment Income$1,365,442CYInvestmentIncomeAmt
PY Other Revenue-$1,899,168PYOtherRevenueAmt
CY Other Revenue$138,187CYOtherRevenueAmt
PY Total Revenue$44,172,260PYTotalRevenueAmt
CY Total Revenue$43,968,062CYTotalRevenueAmt
PY Grants And Similar Paid$5,457,988PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$4,201,474CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$6,235,917PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$8,759,052CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$4,070,238CYTotalFundraisingExpenseAmt
PY Other Expenses$24,548,454PYOtherExpensesAmt
CY Other Expenses$20,627,566CYOtherExpensesAmt
PY Total Expenses$36,242,359PYTotalExpensesAmt
CY Total Expenses$33,588,092CYTotalExpensesAmt
PY Revenues Less Expenses$7,929,901PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$10,379,970CYRevenuesLessExpensesAmt
Total Assets BOY$69,711,900TotalAssetsBOYAmt
Total Assets EOY$79,154,355TotalAssetsEOYAmt
Total Liabilities BOY$21,894,561TotalLiabilitiesBOYAmt
Total Liabilities EOY$23,423,981TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$47,817,339NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$55,730,374NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionSEE SCHEDULE OMissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$6,059,428ExpenseAmt
Grant$3,219,474GrantAmt
Revenue$1,956,025RevenueAmt
DescTHE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SUPPORTS INVESTIGATORS AND SCIENTIFIC PROJECTS THROUGH A NUMBER OF RESEARCH GRANTS. THE GOAL OF THIS INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF THERAPEUTIC APPROACHES FOR MYELOMA THROUGH OUR UNIQUE END-TO-END MODEL THAT SUPPORTS EFFORTS IN BASIC SCIENCE OR TRANSLATION RESEARCH.IN 2017 THE MMRF AWARDED MULTI-YEAR GRANTS FOR THREE NEW PROGRAMS. IN DATA ANALYTICS & ANALYSIS, MMRF AWARDED $2 MILLION TO INVESTIGATORS FOR OUR ANSWER FUND, WHICH WILL LEVERAGE THE LANDMARK MMRF COMMPASS STUDY TO IDENTIFY THE NEXT GENERATION OF THERAPEUTIC TARGETS AND/OR PATHWAYS OR BIOMARKERS FOR HIGH-RISK MULTIPLE MYELOMA (MM) PATIENTS. IN IMMUNOTHERAPY, $7 MILLION WAS AWARDED TO CREATE THE IMMUNE NETWORKS OF EXCELLENCE. THESE MULTICENTER, AND MULTINATIONAL, RESEARCH PARTNERSHIPS OF WORLD-CLASS SCIENTISTS AND CLINICIANS WILL ACCELERATE RESEARCH INTO THE ROLE OF THE PATIENT IMMUNE SYSTEM IN MYELOMA BIOLOGY AND DISEASE PROGRESSION, CHARACTERIZE THE CHANGES IN THE IMMUNE SYSTEM ASSOCIATED WITH THE PATIENT'S RESPONSE OR RESISTANCE TO THERAPY AND IDENTIFY AND DEVELOP NOVEL IMMUNOTHERAPIES AND IMMUNOTHERAPY STRATEGIES. THESE INVESTIGATIVE NETWORKS WILL ALSO COLLECT AND ANALYZE A WIDE RANGE OF KEY IMMUNOLOGICAL DATA FROM PATIENTS AT DIFFERENT DISEASE STAGES AND IMMUNOTHERAPIES THAT WILL BE THE BASIS OF IMMUNE DATABANK. IN 2019 THE MMRF LAUNCHED THE IMMUNE ATLAS, A RESEARCH INITIATIVE TO CREATE A COMPREHENSIVE IMMUNOLOGICAL MAP OF MULTIPLE MYELOMA. THIS INITIATIVE WILL GENERATE HIGH-DIMENSIONAL DATA (DOWN TO THE SINGLE CELL LEVEL) DESCRIBING THE HOW PATIENTS' IMMUNE SYSTEMS CHANGE DURING THE DEVELOPMENT AND PROGRESSION OF MULTIPLE MYELOMA, AND DURING CLINICAL RESPONSE OR NON-RESPONSE TO THERAPY. THE IMMUNE ATLAS INITIATIVE BUILDS UPON THE SCIENTIFIC FOUNDATIONS OF THE COMMPASS GENOMIC STUDY AND THE IMMUNE NETWORKS OF EXCELLENCE PROGRAM, TO PROVIDE A HOLISTIC VIEW OF HOST-DISEASE BIOLOGY AND INTERACTIONS. THE IMMUNE ATLAS INITIATIVE WILL BE CRITICAL TO THE APPLICATION OF IMMUNE THERAPY FOR THE TREATMENT FOR MULTIPLE MYELOMA, FOR DEVELOPING NOVEL BIOMARKERS FOR PATIENT SELECTION, STRATIFICATION AND SEQUENCING OF THERAPIES, FOR SPECIFIC IMMUNE THERAPIES, FOR MONITORING RESPONSE TO TREATMENT AND FOR DRIVING THE IDENTIFICATION OF NOVEL DRUG. ALMOST HALF A MILLION DOLLARS WAS SPENT IN 2019 FOR THIS PROGRAM EXPECTED TO COST $4M OVER THE NEXT TWO YEARS.THE THIRD NEW INITIATIVE IS THE MMRF PREVENTION PROJECT, WHICH FOCUSES ON DETERMINING WHY THE PRECURSOR CONDITIONS MGUS AND SMOLDERING (SMM) QUICKLY PROGRESS TO MM IN SOME PATIENTS AND HOW TO IDENTIFY THIS HIGH-RISK POPULATION. $4 MILLION WAS AWARDED TO FIVE INSTITUTIONS FOR WORK ON THE MMRF PREVENTION PROJECT. AT THE END OF 2019, THE MMRF LAUNCHED THE PRECISION PREVENTION INITIATIVE UNDER THE MMRF PREVENTION PROGRAM. THIS IS A COLLABORATIVE EFFORT BETWEEN THE MMRF CURE CLOUD AND DFCI PRECURSOR STUDIES (PROMISE AND PCROWD). THE MUTUAL GOAL OF THIS 5-YEAR COLLABORATIVE INITIATIVE IS TO FOLLOW SMOLDERING PATIENTS LONGITUDINALLY AND GENERATE A ROBUST GENOMIC/IMMUNE/CLINICAL DATASET WHICH WOULD HELP US REDEFINE THE RISK STRATIFICATION MODELS AND IDENTIFY COMPREHENSIVE PROGNOSTIC AND PREDICTIVE BIOMARKERS OF DISEASE PROGRESSION. THE PREVENTION PROGRAM WILL PROVIDE FUNDING OF UP TO $3.966 MILLION TO SUPPORT THE CORRELATIVE STUDIES AND ASSOCIATED COSTS.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$5,664,303ExpenseAmt
Grant$982,000GrantAmt
Revenue$2,813,345RevenueAmt
DescTHE MULTIPLE MYELOMA RESEARCH CONSORTIUM, LLC. (MMRC) IS A SUBSIDIARY OF THE MULTIPLE MYELOMA RESEARCH FOUNDATION. THE MMRC IS THE FIRST RESEARCH MODEL THAT BRINGS TOGETHER 25 LEADING ACADEMIC CENTERS WITH INDUSTRY PARTNERS TO CONDUCT HIGHLY COLLABORATIVE PHASE 1 AND PHASE 2 CLINICAL TRIALS OF NOVEL COMPOUNDS AND COMBINATION TREATMENTS FOR MULTIPLE MYELOMA. ALL CENTERS ARE DRIVEN BY HIGHLY DEFINED METRICS THAT MANDATE ACCOUNTABILITY AND STRONGLY PROMOTE TEAM SCIENCE. IN 2019, THE MMRF THROUGH THE MMRC OPENED FIRST-EVER PLATFORM CLINICAL TRIAL FOR MULTIPLE MYELOMA AND IS THE IND (INVESTIGATIONAL NEW DRUG) HOLDER, THE MYELOMA-DEVELOPING REGIMENS USING GENOMICS (MYDRUG, NCT03732703). MYDRUGSCREENS PATIENTS' TUMOR SAMPLES FOR GENETIC SIGNATURES AND RANDOMIZE THEM TO APPROPRIATE TARGETED THERAPIES, ALLOWING FOR GREATER EFFICIENCY IN ASSESSING TREATMENT OPTIONS. TOWARD THE END OF 2019, A SECOND PLATFORM STUDY CALLED MYCHECKPOINT (NCT04150965) FOR WHICH THE MMRC IS ALSO THE IND HOLDER WAS APPROVED BY OUR PHARMA PARTNER AND MOVED TOWARD ACTIVATION. WHILE MYDRUG TARGETS UPFRONT HIGH RISK PATIENTS, MYCHECKPOINT IS BRINGING NEW IMMUNOTHERAPIES TO VERY ADVANCED RELAPSED PATIENTS WHO ARE RUNNING OUT OF OPTIONS. AN ADDITIONAL THREE IST CLINICAL TRIALS OPENED IN 2019 AND THE MMRC ENROLLED OVER 160 PATIENTS ACROSS 20 TRIALS. FROM ITS INCEPTION, THE MMRC HAS ENROLLED OVER 2,150 PATIENTS ACROSS MORE THAN 75 CLINICAL TRIALSDesc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$3,998,441ExpenseAmt
DescTHE MMRF LONGITUDINAL STUDY (COMMPASS) COMMENCED IN 2011 AND HAS BEEN EXTENDED THROUGH 2023. MMRF IS THE SPONSOR OF A PERSONALIZED MEDICINE INITIATIVE IN WHICH 1,153 NEWLY DIAGNOSED PATIENTS HAVE BEEN ENROLLED TO DATE THROUGH 108 SITES (I.E., HOSPITALS, ACADEMIC MEDICAL CENTERS AND OTHER COMMUNITY HEALTH CENTERS) ACROSS NORTH AMERICA AND EUROPE. THIS IS AN OBSERVATIONAL STUDY, RATHER THAN AN INTERVENTIONAL ONE WITH EXPERIMENTAL DRUGS BEING TESTED. BIOSPECIMENS (LIKE BLOOD AND BONE MARROW SAMPLES) ARE COLLECTED FROM THE PATIENTS PERIODICALLY OVER THE COURSE OF THEIR TREATMENT ALONG WITH CORRELATING CLINICAL DATA. THE STANDARD OF CARE (I.E., DRUGS AND TREATMENT) FOR EACH PATIENT IS DETERMINED BY SUCH PATIENT'S PERSONAL PHYSICIAN. THE TISSUE SAMPLES COLLECTED ARE PLACED IN A BIOBANK. AN UNRELATED, THIRD PARTY, NOT-FOR-PROFIT BIOMEDICAL RESEARCH INSTITUTE THEN PERFORMS LABORATORY TESTS ON A PORTION OF EACH OF THE SAMPLES RESULTING IN GENOMIC DATA ABOUT EACH PATIENT. OUR GOAL IS TO BUILD AND ANALYZE THE LARGEST FULLY ACCESSIBLE CLINICO-GENOMIC DATASET OF ANY CANCER. THE FINDINGS CANNOT BE PATENTED AND ALL THE DATA ARE PLACED ON A PUBLIC PORTAL (THE MMRF RESEARCHER GATEWAY). THE RESULTING DATA REPOSITORY IS THE MOST COMPREHENSIVE CATALOG OF MULTIPLE MYELOMA AND CONTAINS THE GREATEST AMOUNT OF WHOLE GENOME SEQUENCING DATA OF ANY CANCER, ACCESSIBLE TO ANY RESEARCHER IN THE WORLD. IT WILL PROVIDE FAR MORE INFORMATION THAN IS AVAILABLE FROM CURRENT CANCER TISSUE BANKS THAT TYPICALLY INCLUDE ONLY ONE SAMPLE PER PATIENT.IN 2015, COMMPASS WAS CLOSED TO NEW ENROLLMENT WITH THE AFOREMENTIONED 1,153 PATIENTS WHO ARE BEING FOLLOWED FOR A PERIOD OF 8 YEARS UNTIL 2023. IN DECEMBER 2016, THE MMRF LAUNCHED A SIMILAR SAMPLE/DATA SHARING COLLABORATION WITH ECOG (THE "EASTERN COOPERATIVE ONCOLOGY GROUP"). THE INITIATIVE IS NOW CLOSED TO ENROLLMENT AND ACCRUED APPROXIMATELY 100 NEW SAMPLES.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

FieldValueIRS element (for citing)
Expense$12,988,967ExpenseAmt
DescIN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. ALSO, THE MMRF DEVELOPS AND IMPLEMENTS EXTENSIVE EDUCATIONAL PROGRAMMING FOR HEALTHCARE PROFESSIONALS AND FOR PATIENTS AND CAREGIVERS.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$12,988,967TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses$28,711,139TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Donor Rstr Or Quasi Endowments0DonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other LiabilitiesYes (1)ReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (1)IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt0IndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtYes (1)ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign ActivitiesYes (1)ForeignActivitiesInd
More Than5000 K To OrgYes (1)MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising ActivitiesYes (1)FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To OrganizationsYes (1)GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent0BusinessRlnWith35CtrlEntInd
Deductible Non Cash ContriYes (1)DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded EntityYes (1)DisregardedEntityInd
Related Entity0RelatedEntityInd
Related Organization Ctrl Ent0RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document84IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Employee67EmployeeCnt
Employment Tax Returns FiledYes (1)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo ContributionsYes (1)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (1)QuidProQuoContriDisclInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt0SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members20GoverningBodyVotingMembersCnt
Independent Voting Member18IndependentVotingMemberCnt
Family Or Business RlnYes (1)FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or Stockholders0MembersOrStockholdersInd
Election Of Board Members0ElectionOfBoardMembersInd
Decisions Subject To Approva0DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn BodyYes (1)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (1)WhistleblowerPolicyInd
Document Retention PolicyYes (1)DocumentRetentionPolicyInd
Compensation Process CEOYes (1)CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Other WebsiteYes (X)OtherWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1ROBERT MIANIBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone2036520207PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1383 MAIN AVE 5TH FLOORAddressLine1Txt
CityNORWALKCityNm
State AbbreviationCTStateAbbreviationCd
ZIP06851ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (32 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtKey EmployeeKeyEmployeeIndHighest Compensated EmployeeHighestCompensatedEmployeeInd
PAUL GIUSTI
PRESIDENT & CEO45.00Yes (X)Yes (X)$543,455$0$13,337
KATHY GIUSTI
FOUNDER & CHIEF MISSION OFFICER45.00Yes (X)$396,980$0$1,964
STEVEN LABKOFF MD
CHIEF DATA OFFICER45.00$312,004$0$40,126Yes (X)
ROBERT MIANI
TREASURER/CFO45.00Yes (X)$313,542$0$22,001
MICHAEL ADREINI
COO45.00Yes (X)$260,201$0$16,287
PETER KOSA
MIF MANAGING DIRECTOR45.00$243,184$0$21,851Yes (X)
DANIEL AUCLAIR
CHIEF SCIENTIFIC OFFICER45.00$243,799$0$11,780Yes (X)
ANNE QUINN YOUNG
CHIEF MARKETING & DEV. OFFICER45.00$234,225$0$21,493Yes (X)
CHRISTOPHER WILLIAMS
VP OF BUSINESS DEVELOPMENT45.00$208,150$0$34,080Yes (X)
KAREN DIETZ
SECRETARY/IN-HOUSE COUNSEL45.00Yes (X)$183,823$0$31,228
LAURA GILMAN
VP OF EVENTS45.00$167,295$0$28,430Yes (X)
STEVEN VARLEY
VP OF DEVELOPMENT45.00$185,608$0$9,206Yes (X)
PATRICK SIMMS
VP OF RESEARCH (THRU 12/2019)45.00$166,610$0$28,123Yes (X)
ALICIA O'NEILL
DIR. OF EVENTS BUS. DEV. (THRU 12/2019)45.00$162,137$0$19,888Yes (X)
MICHAEL MORTIMER
CHAIRMAN2.00Yes (X)Yes (X)$0$0$0
LORI TAUBER-MARCUS
VICE CHAIRMAN2.00Yes (X)Yes (X)$0$0$0
KENNETH ANDERSON MD
BOARD MEMBER2.00Yes (X)$0$0$0
KAREN ANDREWS
BOARD MEMBER2.00Yes (X)$0$0$0
TOM CONHEENEY
BOARD MEMBER2.00Yes (X)$0$0$0
RODNEY GILMORE
BOARD MEMBER2.00Yes (X)$0$0$0
W DANA LAFORGE
BOARD MEMBER2.00Yes (X)$0$0$0
DAVID LUCCHINO
BOARD MEMBER2.00Yes (X)$0$0$0
HUGH MARTIN
BOARD MEMBER2.00Yes (X)$0$0$0
SUSAN MARVIN
BOARD MEMBER2.00Yes (X)$0$0$0
GERALD MCDOUGALL
BOARD MEMBER2.00Yes (X)$0$0$0
WILLIAM MCKIERNAN
BOARD MEMBER2.00Yes (X)$0$0$0
DAVID PARKINSON MD
BOARD MEMBER2.00Yes (X)$0$0$0
MARIE PINIZZOTTO MD
BOARD MEMBER2.00Yes (X)$0$0$0
MICHAEL REINERT
BOARD MEMBER2.00Yes (X)$0$0$0
RODGER RINEY
BOARD MEMBER2.00Yes (X)$0$0$0
STEVEN SHAK
BOARD MEMBER2.00Yes (X)$0$0$0
MERYL ZAUSNER
BOARD MEMBER2.00Yes (X)$0$0$0
FieldValueIRS element (for citing)
Total Reportable Comp From Org$3,621,013TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$299,794TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K26IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
REDMEDED LLC
5 GREAT VALLEY PARKWAY SUITE 221MALVERNPA19355CONTINUING MEDICAL EDUCATION$2,010,542
TGEN
445 N FIFTH STREETPHOENIXAZ85004TISSUE & GENE ANALYSIS$1,687,218
PRECISION ONCOLOGY
200 ROUTE 21 NORTH SUITE 102FLEMMINGNJ08822CONTRACT RESEARCH$1,229,108
SYNTERACT HCR INC
5509 SEA OTTER PLACE SUITE 100CARLSBADCA92010CONTRACT RESEARCH$1,151,046
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA02215CONTRACT RESEARCH$900,000
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K31CntrctRcvdGreaterThan100KCnt
Fundraising$9,041,820FundraisingAmt
All Other Contributions$30,609,268AllOtherContributionsAmt
Noncash Contributions$1,099,935NoncashContributionsAmt
Total Contributions$39,651,088TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescRESEARCH & CLINICAL TRIALSDesc
Business541610BusinessCd
Total Revenue Column$2,813,345TotalRevenueColumnAmt
Related Or Exempt Func Income$2,813,345RelatedOrExemptFuncIncomeAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$2,813,345TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,349,522TotalRevenueColumnAmt
Exclusion$1,349,522ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,956,025TotalRevenueColumnAmt
Related Or Exempt Func Income$1,956,025RelatedOrExemptFuncIncomeAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$1,615,920SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$1,600,000SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$15,920SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$15,920TotalRevenueColumnAmt
Exclusion$15,920ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$199,100FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$9,041,820ContriRptFundraisingEventAmt
Fundraising Direct Expenses$2,016,938FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$1,817,838TotalRevenueColumnAmt
Exclusion-$1,817,838ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$43,968,062TotalRevenueColumnAmt
Related Or Exempt Func Income$4,769,370RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion-$452,396ExclusionAmt
FieldValueIRS element (for citing)
Info In Schedule O Part IXYes (X)InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$4,093,974TotalAmt
Program Services$4,093,974ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$107,500TotalAmt
Program Services$107,500ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$2,841,968TotalAmt
Program Services$1,938,823ProgramServicesAmt
Management And General$219,267ManagementAndGeneralAmt
Fundraising$683,878FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$5,008,046TotalAmt
Program Services$3,416,547ProgramServicesAmt
Management And General$386,387ManagementAndGeneralAmt
Fundraising$1,205,112FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$141,735TotalAmt
Program Services$96,693ProgramServicesAmt
Management And General$10,936ManagementAndGeneralAmt
Fundraising$34,106FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$269,435TotalAmt
Program Services$183,811ProgramServicesAmt
Management And General$20,788ManagementAndGeneralAmt
Fundraising$64,836FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$497,868TotalAmt
Program Services$339,652ProgramServicesAmt
Management And General$38,411ManagementAndGeneralAmt
Fundraising$119,805FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

FieldValueIRS element (for citing)
Total$39,935TotalAmt
Program Services$39,935ProgramServicesAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$794,037TotalAmt
Program Services$705,366ProgramServicesAmt
Management And General$6,279ManagementAndGeneralAmt
Fundraising$82,392FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$91,294TotalAmt
Program Services$63,228ProgramServicesAmt
Management And General$5,764ManagementAndGeneralAmt
Fundraising$22,302FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$4,326,029TotalAmt
Program Services$4,150,336ProgramServicesAmt
Management And General$25,811ManagementAndGeneralAmt
Fundraising$149,882FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$148,338TotalAmt
Program Services$28,998ProgramServicesAmt
Management And General$103ManagementAndGeneralAmt
Fundraising$119,237FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$2,760,736TotalAmt
Program Services$1,806,688ProgramServicesAmt
Management And General$18,960ManagementAndGeneralAmt
Fundraising$935,088FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$1,277,483TotalAmt
Program Services$1,058,837ProgramServicesAmt
Management And General$30,342ManagementAndGeneralAmt
Fundraising$188,304FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$273,719TotalAmt
Program Services$196,079ProgramServicesAmt
Management And General$18,851ManagementAndGeneralAmt
Fundraising$58,789FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$529,256TotalAmt
Program Services$246,459ProgramServicesAmt
Management And General$3,482ManagementAndGeneralAmt
Fundraising$279,315FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$127,293TotalAmt
Program Services$119,655ProgramServicesAmt
Management And General$1,106ManagementAndGeneralAmt
Fundraising$6,532FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$263,227TotalAmt
Program Services$218,993ProgramServicesAmt
Management And General$9,604ManagementAndGeneralAmt
Fundraising$34,630FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$147,340TotalAmt
Program Services$93,932ProgramServicesAmt
Management And General$10,624ManagementAndGeneralAmt
Fundraising$42,784FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtFundraisingFundraisingAmt
LS STUDY$4,314,156$4,314,156
CLINICAL TRIALS$3,937,599$3,937,599
GENOMIC ANALYSIS$855,555$855,555
MISC. OPERATING EXPENSE$320,977$277,731$43,246

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$420,592TotalAmt
Program Services$420,592ProgramServicesAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$33,588,092TotalAmt
Program Services$28,711,139ProgramServicesAmt
Management And General$806,715ManagementAndGeneralAmt
Fundraising$4,070,238FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$180,548TotalAmt
Program Services$87,432ProgramServicesAmt
Management And General$0ManagementAndGeneralAmt
Fundraising$93,116FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$4,828,497BOYAmt
EOY$2,767,935EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$2,154,114BOYAmt
EOY$8,175,185EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$18,032,623BOYAmt
EOY$14,668,836EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$2,767,033BOYAmt
EOY$7,399,453EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$882,583BOYAmt
EOY$905,107EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$3,023,097LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$1,381,078LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$1,286,498BOYAmt
EOY$1,642,019EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$39,118,575BOYAmt
EOY$42,886,418EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$550,000BOYAmt
EOY$0EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

FieldValueIRS element (for citing)
EOY$617,425EOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$91,977BOYAmt
EOY$91,977EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$69,711,900BOYAmt
EOY$79,154,355EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$10,995,491BOYAmt
EOY$10,194,365EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$8,569,261BOYAmt
EOY$6,567,903EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$1,596,426BOYAmt
EOY$5,968,343EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$733,383BOYAmt
EOY$693,370EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$21,894,561BOYAmt
EOY$23,423,981EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$30,050,411BOYAmt
EOY$35,142,177EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$17,766,928BOYAmt
EOY$20,588,197EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$47,817,339BOYAmt
EOY$55,730,374EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$69,711,900BOYAmt
EOY$79,154,355EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss$10,379,970ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$1,108,065NetUnrlzdGainsLossesInvstAmt
Prior Period Adjustments-$3,200,000PriorPeriodAdjustmentsAmt
Other Changes In Net Assets-$375,000OtherChangesInNetAssetsAmt
Info In Schedule O Part XIIYes (X)InfoInScheduleOPartXIIInd
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS AuditedYes (1)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (1)AuditCommitteeInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$29,213,174CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$37,196,531CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$44,140,691CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$41,335,585CurrentTaxYearMinus1YearAmt
Current Tax Year$39,651,088CurrentTaxYearAmt
Total$191,537,069TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$29,213,174CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$37,196,531CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$44,140,691CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$41,335,585CurrentTaxYearMinus1YearAmt
Current Tax Year$39,651,088CurrentTaxYearAmt
Total$191,537,069TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$40,262,116SubstantialContributorsTotAmt
Public Support Total170$151,274,953PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$145,653CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$216,547CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$373,452CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,090,003CurrentTaxYearMinus1YearAmt
Current Tax Year$1,349,522CurrentTaxYearAmt
Total$3,175,177TotalAmt
FieldValueIRS element (for citing)
Total Support$194,712,246TotalSupportAmt
Gross Receipts Rltd Activities$19,060,066GrossReceiptsRltdActivitiesAmt
Public Support CY1700.77690PublicSupportCY170Pct
Public Support PY1700.77740PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$635,825OtherCostOrOtherBasisAmt
Depreciation$114,435DepreciationAmt
Book Value$521,390BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$339,402OtherCostOrOtherBasisAmt
Depreciation$157,990DepreciationAmt
Book Value$181,412BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$2,047,870OtherCostOrOtherBasisAmt
Depreciation$1,108,653DepreciationAmt
Book Value$939,217BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$1,642,019TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

FieldValueIRS element (for citing)
DescDEFERRED RENT EXPENSE PAYABLEDesc
Amt$693,370Amt
FieldValueIRS element (for citing)
Total Liability$693,370TotalLiabilityAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$45,247,448TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$1,108,065NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$546,321DonatedServicesAndUseFcltsAmt
Revenue Not Reported$1,654,386RevenueNotReportedAmt
Revenue Subtotal$43,593,062RevenueSubtotalAmt
Other Revenues Not Included$375,000OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt$375,000RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$43,968,062TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$34,134,413TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$546,321DonatedServicesUseFcltsAmt
Expenses Not Reported$546,321ExpensesNotReportedAmt
Expenses Subtotal$33,588,092ExpensesSubtotalAmt
Expenses Not Rpt Fincl Stmt$0ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$33,588,092TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART X, LINE 2:THE MMRF RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE MMRF HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE.
PART XI, LINE 4B - OTHER ADJUSTMENTS:WRITE-OFF UNCOLLECTIBLE PLEDGES REPORTED ON PART XI, LINE 9 375,000.

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)

RegionRegionTxtOfficesOfficesCntEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtRegion Total ExpendituresRegionTotalExpendituresAmt
NORTH AMERICA00GRANTMAKING$32,500
EUROPE (INCLUDING ICELAND & GREENLAND)00GRANTMAKING$75,000
FieldValueIRS element (for citing)
Subtotal Offices0SubtotalOfficesCnt
Subtotal Employees0SubtotalEmployeesCnt
Continuation Total Office0ContinuationTotalOfficeCnt
Continuation Total Employee0ContinuationTotalEmployeeCnt
Total Office0TotalOfficeCnt
Total Employee0TotalEmployeeCnt
Subtotal Spent$107,500SubtotalSpentAmt
Continuation Spent$0ContinuationSpentAmt
Total Spent$107,500TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (2 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxt
NORTH AMERICASITE INVESTMENT GRANT$32,500CHECK
EUROPE (INCLUDING ICELAND & GREENLAND)FELLOW$75,000WIRE
FieldValueIRS element (for citing)
Total501c3 Org2Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt
Transfer To Foreign Corp0TransferToForeignCorpInd
Interest In Foreign Trust0InterestInForeignTrustInd
Foreign Corp Ownership0ForeignCorpOwnershipInd
Passive Foreign Investmest Co0PassiveForeignInvestmestCoInd
Foreign Partnership0ForeignPartnershipInd
Boycott Countries0BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINE 2:MMRF RECEIVES PROGRESS REPORTS ON HOW THE GRANTED FUNDS ARE USED. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE.
PART III ACCOUNTING METHOD:

Schedule G IRS990ScheduleG

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1CHICAGO DINNEREvent1Nm
Gross Receipts Event1$916,040GrossReceiptsEvent1Amt
Charitable Contri Event1$841,140CharitableContriEvent1Amt
Gross Revenue Event1$74,900GrossRevenueEvent1Amt
Non Cash Prizes Event1$297NonCashPrizesEvent1Amt
Rent Facility Costs Event1$98,997RentFacilityCostsEvent1Amt
Entertainment Event1$165,770EntertainmentEvent1Amt
Other Direct Expenses Event1$70,725OtherDirectExpensesEvent1Amt
Event2NEW YORK DINNEREvent2Nm
Gross Receipts Event2$782,340GrossReceiptsEvent2Amt
Charitable Contri Event2$658,140CharitableContriEvent2Amt
Gross Revenue Event2$124,200GrossRevenueEvent2Amt
Non Cash Prizes Event2$256NonCashPrizesEvent2Amt
Rent Facility Costs Event2$189,282RentFacilityCostsEvent2Amt
Food And Beverage Event2$227FoodAndBeverageEvent2Amt
Entertainment Event2$48,470EntertainmentEvent2Amt
Other Direct Expenses Event2$108,456OtherDirectExpensesEvent2Amt
Other Events Total40OtherEventsTotalCnt
Gross Receipts Other Events$7,542,540GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$7,542,540CharitableContriOtherEventsAmt
Oth Direct Expnss Other Events$1,334,458OthDirectExpnssOtherEventsAmt
Gross Receipts Total$9,240,920GrossReceiptsTotalAmt
Charitable Contributions Tot$9,041,820CharitableContributionsTotAmt
Gross Revenue Total Events$199,100GrossRevenueTotalEventsAmt
Non Cash Prizes Total Events$553NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events$288,279RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events$227FoodAndBeverageTotalEventsAmt
Entertainment Total Events$214,240EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$1,513,639OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$2,016,938DirectExpenseSummaryEventsAmt
Net Income Summary-$1,817,838NetIncomeSummaryAmt

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Recipient Table RecipientTable (27 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtPurpose Of GrantPurposeOfGrantTxtAddress Line2USAddress/AddressLine2Txt
BARBARA ANN KARMANOS CANCER HOSPITAL
4100 JOHN R STREETDETROITMI48201201649466501(C)(3)$45,000SITE INVESTMENT GRANT
BAYLOR RESEARCH INSTITUTE - SAMMONS CANCER CENTER
PO BOX 846275DALLASTX75284751921898501(C)(3)$25,000SITE INVESTMENT GRANT
BETH ISREAL DEACONESS MEDICAL CENTER
330 BROOKLINE AVENUEBOSTONMA02215042103881501(C)(3)$270,000SITE INVESTMENT GRANT, IMMUNOTHERAPY
CITY OF HOPE
1500 EAST DUARTE ROAD MEDICALDURATECA91010953435919501(C)(3)$112,500SITE INVESTMENT GRANT, FELLOWOFFICE BLD 3RD FLOOR
DANA FARBER CANCER INSTITUTE
44 BINEY STBOSTONMA02115042263040501(C)(3)$1,380,000SITE INVESTMENT GRANT, FELLOW, PREVENTION PROGRAM
EMORY UNIVERSITY
1365 CLIFTON RD BLDG CATLANTAGA30322580566256501(C)(3)$143,900IMMUNE ANALYSIS, SITE INVESTMENT GRANT, FELLOW
HACKENSACK UNIVERSITY MEDICAL CENTER
360 ESSEX CENTER SUITE 302HACKENSACKNJ07601221487576501(C)(3)$45,000SITE INVESTMENT GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
ONE GUSTAVE L LEVY PLACE PO BOXNEW YORKNY10029136171197501(C)(3)$223,000IMMUNE ANALYSIS, SITE INVESTMENT GRANT1075
LEVINE CANCER CENTER
1021 MOREHEAD MEDICAL DRIVECHARLOTTENC28204560529945501(C)(3)$37,500SITE INVESTMENT GRANT
MASSACHUSETTS GENERAL HOSPITAL
125 NASHUA STREET SUITE 540BOSTONMA02114046011702501(C)(3)$32,500SITE INVESTMENT GRANT
MAYO CLINIC
4500 SAN PABLO ROADJACKSONVILLEFL32224590714831501(C)(3)$25,000SITE INVESTMENT GRANT
MAYO CLINIC
200 FIRST STREET SWROCHESTERMN55905416011702501(C)(3)$83,812IMMUNE ANALYSIS, SITE INVESTMENT GRANT
MAYO CLINIC
13400 EAST SHEA BOULEVARDSCOTTSDALEAZ85259860800150501(C)(3)$25,000SITE INVESTMENT GRANT
MEMORIAL SLOAN-KETTERING CANCER CENTER
1275 YORK AVENUENEW YORKNY10065131924236501(C)(3)$450,643SITE INVESTMENT GRANT, TRANSLATIONAL COE, PREVENTION PROGRAM
NEW YORK UNIVERSITY
25 WEST 4TH STREETNEW YORKNY10012135562308501(C)(3)$100,000PREVENTION PROGRAM
OHIO STATE UNIVERSITY RESEARCH FOUNDATION
B321 STARLING LOVING HALL 320 WESTCOLUMBUSOH43210316401599501(C)(3)$52,000SITE INVESTMENT GRANT10TH AVENUE
ROCKEFELLER UNIVERSITY
1230 YORK AVENUENEW YORKNY10065131624158501(C)(3)$100,000PREVENTION PROGRAM
SARAH CANNON RESEARCH INSTITUTE LLC
3322 WEST END ROAD SUITE 900NASHVILLETN37203201557751$40,000SITE INVESTMENT GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVENUE MC 2115CHICAGOIL60637362177139501(C)(3)$52,500SITE INVESTMENT GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
1515 HOLCOMBEHOUSTONTX77030746001118STATE OF TEXAS$350,000PREVENTION PROGRAM
UCSF MYELOMA RESEARCH PROGRAM
1855 FOLSOM STREET ROOM 423SAN FRANCISCOCA94103946036493501(C)(3)$45,000SITE INVESTMENT GRANT
UNIVERSITY OF MICHIGAN
4310 CANCER CENTER 1500 EASTANN ARBORMI48109386006309501(C)(3)$52,000SITE INVESTMENT GRANTMEDICAL CENTER DRIVE
UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER
5323 HARRY HINES BOULEVARDDALLASTX75390756002868501(C)(3)$40,000SITE INVESTMENT GRANT
UNIVERSITY OF WISCONSIN
21 NORTH PARK STREETMADISONWI53715396006492STATE OF WISCONSIN$75,000FELLOW
VIRGINIA CANCER SPECIALISTS PC
8503 ARLINGTON BLVD SUITE 320FAIRFAXVA22031541795091$25,000SITE INVESTMENT GRANT
WASHINGTON UNIVERSITY IN ST LOUIS
660 E EUCLID AVENUEST LOUISMO63110430653611501(C)(3)$163,619IMMUNE ANALYSIS, SITE INVESTMENT GRANT
YALE UNIVERSITY
PO BOX 2038NEW HAVENCT06520060646973501(C)(3)$100,000PREVENTION PROGRAM
FieldValueIRS element (for citing)
Total501c3 Org25Total501c3OrgCnt
Total Other Org2TotalOtherOrgCnt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 2:FormAndLineReferenceDesc
ExplanationTHERE ARE SEVERAL STEPS THAT LEAD UP TO INDIVIDUAL RESEARCH GRANTS BEING AWARDED: 1. THE OVERALL RESEARCH BUDGET IS PRESENTED TO THE MMRF BOARD. THE BUDGET IS BROKEN DOWN INTO THREE MAIN CATEGORIES WHICH INCLUDE THE FOLLOWING GRANT TYPES: A) CLINIC: CLINICAL- SITE INVESTMENT GRANTS, CLINICAL FUNDING AGREEMENT GRANTS, PRECISION MEDICINE GRANTS B) LEARNING NETWORK: GATEWAYS, DATA ANALYSIS INITIATIVES, TRANSLATIONAL SITE INVESTMENTS GRANTS (MMRF TRANSLATIONAL NETWORK), TRANSLATIONAL AND IMMUNE PROGRAM GRANTS, RESEARCH FELLOW GRANTS. C) DATA BANK: MMRF-SPONSORED LONGITUDINAL MOLECULAR AND IMMUNE STUDIES (COMMPASS AND THE MMRF CURECLOUD). THE BUDGET SPEND IS INITIALLY APPROVED BY THE PROGRAMMING COMMITTEE, AND THEN THE BOARD GIVES FINAL APPROVAL FOR THE RESEARCH SPEND. 2. DURING THE YEAR, THERE ARE MONTHLY RESEARCH SPEND MEETINGS WITH THE CEO AND CFO TO DISCUSS PROGRESS ON MAKING THE AWARDS. ADDITIONALLY, ANY CHANGES OR REFORECASTS ARE DISCUSSED. IF THERE IS A CHANGE GREATER THAN $1M THEN WE MUST GO BACK TO THE PROGRAMMING COMMITTEE TO DISCUSS. 3. THERE ARE TWO DISTINCT TYPES OF GRANTS BEING AWARDED: MORE CLASSICAL RESEARCH SUPPORT GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS. THE ACTUAL AWARDS ARE MADE ACCORDING TO THE BELOW SCHEDULE: A. RESEARCH FELLOW AWARDS- QTR 3 OR QTR 4 B. CLINICAL AND TRANSLATIONAL SITE SUPPORT GRANTS QTR 4 C. OTHER GRANTS ARE MADE THROUGHOUT THE YEAR CLASSICAL RESEARCH GRANTS: CLASSICAL RESEARCH GRANTS ARE AWARDED ON THE BASIS OF THE FOLLOWING PROCESS: GRANTS ARE REVIEWED BY AN EXTERNAL GROUP OF SCIENTISTS WITH THE APPROPRIATE AREAS OF EXPERTISE. SCIENTIFIC RATINGS USE THE CURRENT NIH SCORING SYSTEM OF 1-9 WITH 1 DEMONSTRATING THE HIGHEST SCIENTIFIC MERIT AND 9 BEING THE LOWEST. EACH PROPOSAL IS EVALUATED BY TWO INDEPENDENT OUTSIDE REVIEWERS AND THE SCORES ARE AVERAGED TOGETHER. MOST GRANTS CHOSEN SCORE AT LEAST A 3 OR BETTER. ONCE THE GRANTS ARE RATED EXTERNALLY, FINAL REVIEW IS DONE BY THE MMRF RESEARCH LEADERSHIP AND RECOMMENDATIONS ARE MADE TO THE CEO TO CONFIRM THE FINAL SELECTION. AFTER EACH GRANT TYPE AWARD IS MADE, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO AND THE ASSOCIATE DIRECTOR OF FINANCE NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. ALSO, WE HAVE A CONFLICT OF INTEREST POLICY AND A COMMITTEE THAT REVIEWS ANY ISSUES. AFTER THE FIRST PAYMENT THE RESEARCHER SENDS IN THE REQUIRED PROGRESS REPORT TO RECEIVE REMAINING PAYMENTS. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS THAT APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS: GRANT PROPOSALS TO SUPPORT MMRF/C CLINICAL OR TRANSLATIONAL SITES ARE REVIEWED BY MMRF RESEARCH STAFF AND LEADERSHIP IN COLLABORATION WITH OUTSIDE ADVISORS. SIMILAR TO CLASSICAL GRANTS, MMRF RESEARCH LEADERSHIP THEN MAKES RECOMMENDATIONS TO THE CEO FOR FINAL APPROVAL. AFTER EACH GRANT TYPE AWARD IS APPROVED, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO AND THE ASSOCIATE DIRECTOR OF FINANCE NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. SUCH GRANTS ARE TYPICALLY RENEWED ANNUALLY OR ARE MULTI-YEAR IN NATURE. CONTINUATION/RENEWAL IS AWARDED BASED ON MILESTONES ESTABLISHED UPON INITIATION OF THE PROGRAM. CONFLICT OF INTEREST POLICY AND COMMITTEE OVERSIGHT ALSO APPLY HERE.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr Plan0SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (1)AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
PAUL GIUSTI
PRESIDENT & CEO$441,000$0$100,000$0$2,455$0$11,200$0$2,137$0$556,792$0$0$0
KATHY GIUSTI
FOUNDER & CHIEF MISSION OFFICER$325,000$0$70,000$0$1,980$0$0$0$1,964$0$398,944$0$0$0
STEVEN LABKOFF MD
CHIEF DATA OFFICER$300,586$0$0$0$11,418$0$11,200$0$28,926$0$352,130$0$0$0
ROBERT MIANI
TREASURER/CFO$230,063$0$69,600$0$13,879$0$11,200$0$10,801$0$335,543$0$0$0
MICHAEL ADREINI
COO$193,993$0$60,000$0$6,208$0$10,454$0$5,833$0$276,488$0$0$0
PETER KOSA
MIF MANAGING DIRECTOR$232,282$0$0$0$10,902$0$9,974$0$11,877$0$265,035$0$0$0
DANIEL AUCLAIR
CHIEF SCIENTIFIC OFFICER$204,300$0$22,000$0$17,499$0$9,733$0$2,047$0$255,579$0$0$0
ANNE QUINN YOUNG
CHIEF MARKETING & DEV. OFFICER$196,759$0$22,000$0$15,466$0$9,742$0$11,751$0$255,718$0$0$0
CHRISTOPHER WILLIAMS
VP OF BUSINESS DEVELOPMENT$180,816$0$20,000$0$7,334$0$8,755$0$25,325$0$242,230$0$0$0
KAREN DIETZ
SECRETARY/IN-HOUSE COUNSEL$151,384$0$20,000$0$12,439$0$7,858$0$23,370$0$215,051$0$0$0
LAURA GILMAN
VP OF EVENTS$138,254$0$15,000$0$14,041$0$7,110$0$21,320$0$195,725$0$0$0
STEVEN VARLEY
VP OF DEVELOPMENT$176,671$0$0$0$8,937$0$0$0$9,206$0$194,814$0$0$0
PATRICK SIMMS
VP OF RESEARCH (THRU 12/2019)$165,971$0$0$0$639$0$6,682$0$21,441$0$194,733$0$0$0
ALICIA O'NEILL
DIR. OF EVENTS BUS. DEV. (THRU 12/20$136,942$0$12,000$0$13,195$0$6,547$0$13,341$0$182,025$0$0$0

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 7FormAndLineReferenceDesc
ExplanationTHE FOLLOWING EMPLOYEES RECEIVED A BONUS FROM THE ORGANIZATION. EACH BONUS WAS BASED ON THE DISCRETION OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS. EACH BONUS WAS BASED UPON A REVIEW OF THE INDIVIDUAL'S PERFORMANCE, AND APPROVED BY THE COMPENSATION COMMITTEE PRIOR TO BEING AWARDED. PAUL GIUSTI, PRESIDENT & CEO $100,000 KATHY GIUSTI, FOUNDER & CMO $70,000 ROBERT MIANI, TREASURER/CFO $69,600 MICHAEL ADREINI, COO $60,000 KAREN DIETZ, SECRETARY & IN-HOUSE COUNSEL $20,000 ANNE QUINN YOUNG, CHIEF MARKETING & DEVELOPMENT OFFICER $22,000 DANIEL AUCLAIR, CHIEF SCIENTIFIC OFFICER $22,000 LAURA GILMAN, VP OF EVENTS $15,000 ALICIA O'NEIL, DIRECTOR OF EVENTS BUSINESS DEVELOPMENT & PARTNERSHIPS $12,000 CHRISTOPHER WILLIAMS, VP OF BUSINESS DEVELOPMENT $20,000ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution39ContributionCnt
Noncash Contributions Rpt F990$1,099,935NoncashContributionsRptF990Amt
Method Of Determining RevenuesAVG. SELLING PRICEMethodOfDeterminingRevenuesTxt
FieldValueIRS element (for citing)
Form8283 Received0Form8283ReceivedCnt
Any Property That Must Be Held0AnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (1)ReviewProcessUnusualNCGiftsInd
Third Parties Used0ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, COLUMN (B):FormAndLineReferenceDesc
ExplanationTHE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (11 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART I, LINE 1:MMRF ACCOMPLISHMENTS FOR 2019 THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) HAS BUILT ON THE SUCCESSES OF 2018 AND HAD A BANNER YEAR IN 2019, WHICH INCLUDED THE LAUNCH OF ITS LATEST THREE-YEAR STRATEGIC PLAN. THE MMRF HAS BEEN A CATALYST IN TRANSFORMING THE CANCER RESEARCH AND TREATMENT LANDSCAPE. WE HAVE ACCELERATED THE DEVELOPMENT OF NOVEL TREATMENTS, FUELED MORE CLINICAL STUDIES AND, ULTIMATELY, BENEFITED THOUSANDS OF MULTIPLE MYELOMA PATIENTS. WITH OUR BOLD SMARTER FASTER CURE STRATEGIC PLAN, WE HAVE CONTINUED OUR RELENTLESS PURSUIT OF OUR MISSION: - WE ARE WORKING SMARTER. WE HAVE BROUGHT OUR RIGOROUS BUSINESS APPROACH TO IMMUNO-ONCOLOGY THE NEXT FRONTIER IN CANCER RESEARCH AND TREATMENT. BY COLLECTING AND SHARING VITAL DATA AND ACTIVATING NEW CLINICAL TRIALS, WE WILL BRING BETTER, MORE PRECISE TREATMENTS TO MULTIPLE MYELOMA. - WE ARE WORKING FASTER. WE ARE ATTRACTING NEW PARTNERS, CLINICAL ASSETS, AND TECHNOLOGIES TO THE MULTIPLE MYELOMA SPACE THROUGH THE FIRST-EVER VENTURE PHILANTHROPY FUND EXCLUSIVELY FOCUSED ON THIS DISEASE. - ABOVE ALL ELSE, WE ARE WORKING TOWARD A CURE. BUILDING ON THE SUCCESSFUL FOUNDATION OF THE COMMPASS STUDY, THE MMRF CURECLOUD AIMS TO DEMOCRATIZE ACCESS TO TECHNOLOGY AND DATA THAT WILL IMPROVE THE CARE AND OUTCOME OF EVERY MULTIPLE MYELOMA PATIENT. SMARTER INITIATING BREAKTHROUGHS IN IMMUNE-ONCOLOGY AND GENOMICS - IN MARCH 2019, THE MMRF BROUGHT TOGETHER LEADERS FROM ACADEMIA, BIOTECH, AND PHARMACEUTICAL INDUSTRIES, AS WELL AS THE MULTIPLE MYELOMA RESEARCH CONSORTIUM TO CONVENE THE FIRST-EVER IMMUNE SUMMIT AT ITS NORWALK, CT HEADQUARTERS. THE IMMUNE SUMMIT SOUGHT TO ADDRESS AND ADVANCE KEY PRIORITIES IN IMMUNO-ONCOLOGY, INCLUDING BUILDING AN IMMUNE ATLAS, DRIVING CLINICAL ACCELERATION, AND ADVANCING PRECISION PREVENTION. FASTER ACCELERATING INVESTMENT AND SCALE THROUGH A VENTURE FUND - IN 2019, THE MMRF LAUNCHED THE MYELOMA INVESTMENT FUND. FOCUSED ON ACCELERATING THE MMRF'S MISSION TO DELIVER PRECISION MEDICINE TO EVERY PATIENT, THE FUND HAS MADE THREE INVESTMENTS INTO TWO COMPANIES, NEXIMMUNE AND TIDAL THERAPEUTICS, AND HAS SEVERAL INVESTMENTS SET TO CLOSE IN 2020. CURE DEMOCRATIZING ACCESS TO DATA TO OPTIMIZE PATIENT CARE AND IDENTIFY NEW TARGETS - THE MMRF'S LANDMARK COMMPASS STUDY THE LARGEST GENOMIC DATASET OF ANY CANCER CONTINUES TO SUPPORT PATIENT TREATMENT AND FUEL NEW INSIGHTS. TO DATE, 1,038 COMMPASS PATIENTS HAVE HAD THEIR BASELINE MOLECULAR PROFILES COMPLETED; 257 HAD THEIR RELAPSE SAMPLES SEQUENCED AND, OF THOSE, 67 WERE PROVIDED A REPORT. IN 2019, COMMPASS DATA RESULTED IN 41 NEW SCIENTIFIC PUBLICATIONS AND 18 RESEARCH ABSTRACTS, WHICH THE MMRF PRESENTED THE PROMINENT INTERNATIONAL MYELOMA WORKSHOP (IMW) IN DECEMBER 2019. THE MMRF ALSO PRESENTED ANOTHER 6 ABSTRACTS FROM MMRC TRIALS, THE MMRF ANSWER FUND, AND THE MMRF IMMUNOTHERAPY INITIATIVES AT THE IMW - THE MMRF BEGAN THE LAUNCH OF THE MMRF CURECLOUD. AS THE FIRST AND MOST COMPREHENSIVE DATA REPOSITORY OF ITS KIND IN MYELOMA, THE CURECLOUD WILL BE CRUCIAL TO IMPROVING PATIENT CARE AND OUTCOMES. IN 2019, THE MMRF COMPLETED A PILOT STUDY WITH APPROXIMATELY 200 PATIENTS, WHICH VALIDATED OUR APPROACH AND CONFIRMED THE FEASIBILITY OF THE CURECLOUD DATA AND DISCOVERY PLATFORM. THE CURECLOUD WILL FULLY LAUNCH IN JULY 2020. IN ADDITION, THE MMRF HAS CONTINUED ITS WORK IN CLINICAL ADVANCEMENT AND IN SUPPORTING PATIENTS DIRECTLY THROUGH SUMMITS, WEBINARS, AND ITS NEW PATIENT NAVIGATION CENTER. CLINIC DELIVERING NEW THERAPIES TO THE PATIENTS WHO NEED THEM - IN 2019, THE MMRF THROUGH THE MMRC HAD 17 OPEN AND ENROLLING TRIALS, INCLUDING 3 NEWLY OPENED TRIALS. ULTIMATELY, THE MMRF ENROLLED NEARLY 148 PATIENTS ACROSS 17 TRIALS. - BY 2019 YEAR-END, 17 SITES WERE ACTIVE AND ENROLLING PATIENTS IN THE ONLY PLATFORM TRIAL IN MULTIPLE MYELOMA, THE MMRF MYDRUG TRIAL. THIS TRIAL REPRESENTS THE PINNACLE OF PRECISION MEDICINE AND WAS MADE POSSIBLE USING GENOMIC FINDINGS DISCOVERED IN THE COMMPASS STUDY. PATIENT SERVICES AND EDUCATION ADVANCING PATIENT HEALTH AND WELL-BEING THROUGH EDUCATION - PATIENT EDUCATION WEBINARS AND SUMMITS REACHED 10,000 PATIENTS AND CAREGIVERS IN 2019. - SINCE IT FIRST OPENED IN APRIL 2019, THE MMRF PATIENT NAVIGATION CENTER HAS ANSWERED MORE THAN 3,000 CALLS, ADDRESSED MORE THAN 2,200 CASES, AND ANSWERED NEARLY 800 QUESTIONS FROM WEBINAR ATTENDEES. ITS EXEMPLARY SERVICE HAS EARNED A 98% SATISFACTION RATING FROM THE MYELOMA COMMUNITY. ORGANIZATIONAL UPDATES - THE MMRF ALSO EXPANDED ITS LEADERSHIP TEAM IN 2019, WELCOMING HEARN JAY CHO, MD, PHD AS CHIEF MEDICAL OFFICER; MICHAEL ANDREINI AS CHIEF OPERATING OFFICER; AND PETER KOSA AS MANAGING DIRECTOR OF THE MYELOMA INVESTMENT FUND.
FORM 990, PART III, LINE 1:A PIONEER IN PRECISION MEDICINE, THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SEEKS TO FIND A CURE FOR ALL MULTIPLE MYELOMA PATIENTS BY RELENTLESSLY PURSUING INNOVATIONS THAT ACCELERATE THE DEVELOPMENT OF PRECISION TREATMENTS FOR CANCER. FOUNDED IN 1998 BY KATHY GIUSTI, A MULTIPLE MYELOMA PATIENT, AND HER TWIN SISTER KAREN ANDREWS AS A 501(C)(3) NONPROFIT ORGANIZATION, THE MMRF HAS CREATED THE BUSINESS MODEL AROUND CANCERFROM DATA TO ANALYTICS TO THE CLINIC. THE MMRF IDENTIFIES BARRIERS AND THEN FINDS THE SOLUTIONS TO OVERCOME THEM, BRINGING IN THE BEST PARTNERS AND ALIGNING INCENTIVES IN THE INDUSTRY TO DRIVE BETTER OUTCOMES FOR PATIENTS. SINCE ITS INCEPTION, THE ORGANIZATION HAS COLLECTED THOUSANDS OF SAMPLES AND TISSUES, OPENED NEARLY 100 TRIALS, HELPED BRING 12 FDA-APPROVED THERAPIES TO MARKET, AND BUILT COMMPASS, THE SINGLE LARGEST GENOMIC DATASET FOR ANY CANCER. TODAY, THE MMRF IS BUILDING ON ITS LEGACY IN GENOMICS AND IS EXPANDING INTO IMMUNOTHERAPY, AS THE COMBINATION OF THESE TWO FIELDS WILL BE CRITICAL TO MAKING PRECISION MEDICINE POSSIBLE FOR ALL PATIENTS. THE MMRF HAS RAISED NEARLY $500 MILLION AND DIRECTS NEARLY 90% OF THE TOTAL FUNDS TO RESEARCH AND RELATED PROGRAMS.
FORM 990, PART VI, SECTION A, LINE 2THE FOLLOWING BOARD MEMBERS, KATHY GIUSTI, FOUNDER & CHIEF MISSION OFFICER, KAREN ANDREWS, BOARD MEMBER, AND PAUL GIUSTI, PRESIDENT & CEO, ALL HAVE A FAMILY RELATIONSHIP.
FORM 990, PART VI, SECTION B, LINE 11BTHE FORM 990 IS FIRST REVIEWED WITH THE CEO OF THE FOUNDATION. ONCE REVIEWED WITH THE CEO, THE FORM 990 IS EMAILED TO EACH BOARD MEMBER. EACH BOARD MEMBER REVIEWS THE FORM 990 AND IF ANY QUESTIONS ARISE, THEY ARE COMMUNICATED TO THE FOUNDATION AND ADDRESSED. AFTER ALL QUESTIONS ARE ADDRESSED, THE FORM 990 IS SUBMITTED TO THE IRS.
FORM 990, PART VI, SECTION B, LINE 12CDUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST: ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR CONFLICTS COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE CONFLICTS COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR CONFLICTS COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR CONFLICT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR CONFLICTS COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE CONFLICTS COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE CONFLICTS COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR CONFLICT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRF'S BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRF'S CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY: III. IF THE BOARD OR CONFLICTS COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR CONFLICTS COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR CONFLICTS COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.
FORM 990, PART VI, SECTION B, LINE 15ALL SENIOR POSITIONS AND THEIR COMPENSATION ARE REVIEWED AND APPROVED BY THE HR COMMITTEE OF THE BOARD OF DIRECTORS. COMPENSATION FOR EMPLOYEES ARE BENCHMARKED AGAINST OTHER 501(C)(3)'S AND RESEARCH ORGANIZATIONS, THEN REVIEWED BY THE COMPENSATION COMMITTEE. THE COMPENSATION APPROVAL IS DOCUMENTED IN THE MINUTES BY THE COMMITTEE. THIS PROCESS WAS LAST UNDERTAKEN IN 2019.
FORM 990, PART VI, SECTION C, LINE 19FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FORM 990 AND FORM 1023 ARE MADE AVAILABLE FOR PUBLIC VIEWING UPON WRITTEN REQUEST AT MMRF'S HEADQUARTERS LOCATED AT 383 MAIN AVENUE, 5TH FLOOR, NORWALK, CT 06851. FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE AT THE ORGANIZATION'S WEBSITE: WWW.THEMMRF.ORG THE FORM 990 IS ALSO AVAILABLE ON WWW.GUIDESTAR.ORG, WWW.CHARITYNAVIGATOR.ORG, AND OTHER SIMILAR WEBSITES.
FORM 990, PART IX, LINE 11GCONSULTING: PROGRAM SERVICE EXPENSES 1,564,738. MANAGEMENT AND GENERAL EXPENSES 7,102. FUNDRAISING EXPENSES 59,916. TOTAL EXPENSES 1,631,756. RECRUITING COSTS & TEMPORARY HELP: PROGRAM SERVICE EXPENSES 348,871. MANAGEMENT AND GENERAL EXPENSES 16,440. FUNDRAISING EXPENSES 82,358. TOTAL EXPENSES 447,669. MEDICAL EDUCATION PROVIDERS: PROGRAM SERVICE EXPENSES 2,196,166. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,196,166. HR FEES: PROGRAM SERVICE EXPENSES 20,066. MANAGEMENT AND GENERAL EXPENSES 2,269. FUNDRAISING EXPENSES 7,078. TOTAL EXPENSES 29,413. MEDICAL WRITERS: PROGRAM SERVICE EXPENSES 20,495. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 530. TOTAL EXPENSES 21,025.
FORM 990, PART XI, LINE 9:WRITE-OFF OF UNCOLLECTIBLE PLEDGES -375,000.
FORM 990, PART XII, LINE 2C:THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AUDIT/FINANCE COMMITTEE RECOMMENDS THE AUDITOR TO THE BOARD, AND THE BOARD APPOINTS THE AUDITOR. THE BOARD ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR.
FORM 990, PART XI, LINE 8:A. EFFECTIVE JANUARY 1, 2019, THE MMRF ADOPTED NEW U.S. GAAP REVENUE RECOGNITION GUIDANCE, ACCOUNTING STANDARDS UPDATE 2014-09, REVENUE FROM CONTRACTS WITH CUSTOMERS (TOPIC 606) ("ASU 2014-09"), WHICH PROVIDES A SINGLE COMPREHENSIVE MODEL FOR ENTITIES TO USE IN ACCOUNTING FOR REVENUE ARISING FROM CONTRACTS WITH CUSTOMERS AND SUPERSEDES MOST CURRENT REVENUE RECOGNITION GUIDANCE. ADOPTION OF ASU 2014-09 RESULTED IN AN OPENING ADJUSTMENT TO OPENING NET ASSETS OF $3,200,000 TO RECOGNIZE OPENING DEFERRED REVENUE AS OF JANUARY 1, 2019.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp (2 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdTotal IncomeTotalIncomeAmtEnd Of Year AssetsEndOfYearAssetsAmtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1Txt
MYELOMA INVESTMENT FUND LLC
383 MAIN AVENUE 5TH FLOORNORWALKCT06851471162865VENTURE PHILANTHROPY FUNDDE$2,555,427$12,844,986THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC
383 MAIN AVENUE 5TH FLOORNORWALKCT06851471142650FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCHCT$5,228,089$3,363,621THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.